Innoskel

Innoskel is a pioneering platform biotechnology company focusing on developing novel therapies for rare bone diseases. The company's inaugural asset targets a group of rare skeletal disorders, particularly type 2 collagenopathies, with a specific focus on Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism globally. Innoskel's lead gene therapy asset for SEDc has shown promising efficacy in proof-of-concept studies. Founded in 2020 and headquartered in France, the company recently secured a substantial €20.00M Series A investment on 14 December 2020, led by Jeito Capital, Turenne Capital, Vida Ventures, and Région Sud Investissement. Innoskel's fundamental mission revolves around enhancing the quality of life for individuals with rare bone disorders, ensuring that their unmet needs are addressed with their perspectives at the forefront of all endeavors.